《股市简讯》中国复宏汉霖一度涨4.6%创新高，眼科药物上市申请获药监局受理

路透中文

08/14

《股市简讯》中国<a href="https://laohu8.com/S/02696">复宏汉霖</a>一度涨4.6%创新高，眼科药物上市申请获药监局受理

* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周四早盘一度升4.6%，创2019年上市以来新高，早市收涨0.7%。

* 该公司此前公告称，眼用注射液HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。

* 复宏汉霖今年迄今暴涨226.8%，同期恒生指数.HSI大幅上扬27.6%。

* 恒生香港上市生物科技指数.HSHKBIO早盘收高1.1%。（完）

更多股市简讯请点选CN-CMN-HOT

(发稿徐凯文；审校田镧沁)

((kaiwen.xu@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559855939"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559855939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559855939?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-08-14 12:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559855939","market":"us","top_or_hot":-1,"title":"《股市简讯》中国复宏汉霖一度涨4.6%创新高，眼科药物上市申请获药监局受理","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>一度涨4.6%创新高，眼科药物上市申请获药监局受理</title></head><body><p>* 中国<a href=\"https://laohu8.com/S/600196\">复星医药</a><span>2196.HK</span><span>600196.SS</span>旗下研发<a href=\"https://laohu8.com/S/000504\">生物</a>类似药的复宏汉霖<span>2696.HK</span>周四早盘一度升4.6%，创2019年上市以来新高，早市收涨0.7%。</p><p>* 该公司此前公告称，眼用注射液HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。</p><p>* 复宏汉霖今年迄今暴涨226.8%，同期恒生指数<span>.HSI</span>大幅上扬27.6%。</p><p>* 恒生香港上市生物科技指数<span>.HSHKBIO</span>早盘收高1.1%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 田镧沁)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国复宏汉霖一度涨4.6%创新高，眼科药物上市申请获药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国复宏汉霖一度涨4.6%创新高，眼科药物上市申请获药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-08-14 12:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中国<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>一度涨4.6%创新高，眼科药物上市申请获药监局受理</title></head><body><p>* 中国<a href=\"https://laohu8.com/S/600196\">复星医药</a><span>2196.HK</span><span>600196.SS</span>旗下研发<a href=\"https://laohu8.com/S/000504\">生物</a>类似药的复宏汉霖<span>2696.HK</span>周四早盘一度升4.6%，创2019年上市以来新高，早市收涨0.7%。</p><p>* 该公司此前公告称，眼用注射液HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。</p><p>* 复宏汉霖今年迄今暴涨226.8%，同期恒生指数<span>.HSI</span>大幅上扬27.6%。</p><p>* 恒生香港上市生物科技指数<span>.HSHKBIO</span>早盘收高1.1%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 田镧沁)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nL4T3U608K:1","article_id":"2559855939","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559855939","pubTimestamp":1755146177,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国复宏汉霖一度涨4.6%创新高，眼科药物上市申请获药监局受理* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周四早盘一度升4.6%，创2019年上市以来新高，早市收涨0.7%。* 该公司此前公告称，眼用注射液HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。* 复宏汉霖今年迄今暴涨226.8%，同期恒生指数.HSI大幅上扬27.6%。* 恒生香港上市生物科技指数.HSHKBIO早盘收高1.1%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","02696":"复宏汉霖","BK0060":"抗癌","BK0239":"医药制造","BK0187":"一线龙头","BK0028":"国家队","BK0096":"民营医院","BK0183":"MSCI概念","BK1161":"生物科技","BK0188":"融资融券","BK1515":"抗疫概念","BK1191":"制药","BK0175":"白马股","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","02196":"复星医药"},"translate_title":"\"Stock Market Newsletter\" China Henlius once rose 4.6% to a new high, and the ophthalmic drug listing application was accepted by the Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"02196":0.9,"02696":0.9},"content_text":"《股市简讯》中国复宏汉霖一度涨4.6%创新高，眼科药物上市申请获药监局受理* 中国复星医药2196.HK600196.SS旗下研发生物类似药的复宏汉霖2696.HK周四早盘一度升4.6%，创2019年上市以来新高，早市收涨0.7%。* 该公司此前公告称，眼用注射液HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。* 复宏汉霖今年迄今暴涨226.8%，同期恒生指数.HSI大幅上扬27.6%。* 恒生香港上市生物科技指数.HSHKBIO早盘收高1.1%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 田镧沁) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}